bioAffinity Technologies alternatives and competitors
The closest alternatives to bioAffinity Technologies are GRAIL, Freenome, Veracyte and Samay.
bioAffinity Technologies (NASDAQ: BIAF) develops noninvasive tests for lung disease, led by CyPath Lung, a laboratory developed test that pulmonologists and other physicians order for high risk patients with indeterminate pulmonary nodules.
10 alternatives to bioAffinity Technologies
What each product does, with its price as the vendor publishes it.
-
G
Multi cancer early detection company (NASDAQ: GRAL). The Galleri test uses targeted methylation sequencing of cell free DNA from a blood draw, with machine learning classifiers that detect a cancer signal and predict its origin, across more than 50 cancer types.
Price: $949 per test (list price)
-
F
Cancer screening company (NASDAQ: FRNM) whose blood tests run on a multiomics platform that reads cell free DNA methylation at single base resolution, alongside protein and autoantibody signals, with machine learning classifiers producing the result.
Price: No published price
-
V
Veracyte sells genomic tests that pair a laboratory expression assay with a learned classifier, used by urologists, oncologists and endocrinologists to decide how intensively to treat a cancer or whether a thyroid nodule needs surgery.
Price: No published price
-
S
Respiratory diagnostics company developing Sylvee, a chest worn wearable that projects low frequency sound into the lungs and analyzes the returning resonance with machine learning to measure lung volumes, trapped air, respiratory rate and breathing sounds, positioned for early COPD…
Price: No published price
-
B
Precision oncology company in Waltham, Massachusetts, combining sequencing in its own CAP accredited, CLIA certified laboratory with models of tumor and immune biology.
Price: No published price
-
H
Genomics company in San Mateo, California, sequencing with its proprietary Exome+ assay in a CLIA certified, CAP accredited laboratory.
Price: No published price
-
O
Optellum, based in Oxford with a US office in Houston, sells the Virtual Nodule Clinic, which identifies patients with pulmonary nodules, triages and tracks them, and scores malignancy risk with its Lung Cancer Prediction AI, a convolutional neural network applied to the CT scan.
Price: No published price
-
C
Caris Life Sciences (NASDAQ: CAI) is a precision oncology company in Irving, Texas. It profiles tumors in its own laboratories by whole exome and whole transcriptome sequencing and layers AI signatures on the results.
Price: No published price
-
A
Allelica, based in San Francisco, builds polygenic risk scores and sells them several ways.
Price: No published price
-
I
Imagene AI reads routine stained lung cancer slides and predicts which gene changes a tumor carries, without using more tissue for sequencing.
Price: No published price
bioAffinity Technologies alternatives, answered
What are the best alternatives to bioAffinity Technologies?
The closest alternatives to bioAffinity Technologies are GRAIL, Freenome, Veracyte, Samay and BostonGene. Veracyte sells genomic tests that pair a laboratory expression assay with a learned classifier, used by urologists, oncologists and endocrinologists to decide how intensively to treat a cancer or whether a thyroid nodule needs surgery.
Who are bioAffinity Technologies's competitors?
bioAffinity Technologies's competitors in the Diagnostics & Genomics category include GRAIL, Freenome, Veracyte, BostonGene, Helix and Caris Life Sciences.